WallStSmart
BNBX

Applied DNA Sciences, Inc.

NASDAQ: BNBX · FINANCIAL SERVICES · ASSET MANAGEMENT

$0.47
+4.52% today

Updated 2026-06-05

Market cap
$3.59M
P/E ratio
0.00
P/S ratio
1.96x
EPS (TTM)
$370.17
Dividend yield
52W range
$0 – $7
Volume
1.1M

Applied DNA Sciences, Inc. (BNBX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20212022202320242025
Operating cash flow$-13.39M$-8.98M$-6.22M$-13.71M$-12.52M
Capital expenditures$2.55M$489553.00$78448.00$407904.00$313121.00
Depreciation
Stock-based comp$1.67M$2.52M$1.03M$572293.00$102021.00
Free cash flow$-15.94M$-9.47M$-6.30M$-14.12M$-12.83M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Applied DNA Sciences, Inc.'s revenue?

Applied DNA Sciences, Inc.'s trailing twelve-month revenue is $1.83M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is BNBX?

In its most recent fiscal year, BNBX ran a gross margin of 39.26%, an operating margin of -750.92%, and a net margin of -709.46%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does BNBX generate?

BNBX produced $-12.83M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BNBX's balance sheet healthy?

BNBX holds $1.67M in cash and equivalents against — in long-term debt, on $2.30M of shareholder equity. That debt is best read against the cash flow the business throws off each year.